Masimo Corporation (MASI) announced that it has signed a new worldwide technology licensing agreement with GS Elektromedizinische Gerate G. Stemple GmbH that will enable the latter to integrate Masimo’s Rainbow SET Pulse CO-Oximetry into its corpuls patient monitoring modules. GS Elektromedizinische Gerate G. Stemple GmbH is a leading German company that develops and manufactures innovative medical equipment for Emergency Medical Services (EMS) and intensive care. The company is a market leader in providing innovative EMS solutions throughout Europe. The company’s corpuls patient monitoring modules and defibrillators are used in the first aid treatment of patients suffering from sudden cardiac arrest. Masimo’s Rainbow SET Pulse CO-Oximetry allows for continuous monitoring of hemoglobin, carbon monoxide, methemoglobin, PVI for fluid responsiveness, perfusion index and measure-through motion pulse oximetry. The integration of the Rainbow SET Pulse CO-Oximetry will enhance the efficiency of GS GmbH’s defibrillators and patient monitoring systems ...

Mindray Medical International Ltd. (MR) posted second-quarter results prior to the opening bell today. GAAP net income recorded a strong growth of 37.2% year over year to $33.0 million. Excluding amortization of intangibles and certain other items, earnings per share came in at 31 cents, topping the Zacks Consensus Estimate by nearly 7%, or 2 cents. The China-based company reported a growth of nearly 10% year over year to $160.1 million. The expansion was driven by Chinese operations, which grew 31.3% to $75.9 million helped by the launch of new products and stimulus funding by the government. The growth was partially offset by a 4.2% decline in international operations to $84.1 million, as performance was hurt by sluggish hospital spending in the U.S. Mindray is a leading developer, manufacturer and marketer of medical devices based in China. The company offers more than 40 products across three ...

span class=”Apple-style-span” style=”font-weight: bold;”Authentidate Holding Corp (ncm: ADAT) $0.27/span- Authentidate is attractively positioned to benefit from the expected flood of spending aimed at modernizing healthcare IT. Remote patient monitoring, also known as telehealth, is one area where Authentidate stands to capitalize due to its unique and superior product solution. Patient home monitoring is expected to be a $12 billion industry by 2012. ADAT will earn $120M in revenue if it achieves just 1% penetration. This compares to $6M in revenue Authentidate earned last fiscal year. There are a decent number of patient monitoring devices deployed currently, yet very few have actual “telemedicine” functionality, whereby a patient’s vitals are electronically transmitted to the healthcare provider coupled with any patient instructions subsequently relayed back to the patient. According to an InMedica study, there were less than 1 million telehealth subscribers in 2008, yet that number is expected to climb to over 55 …